Merck & Co. bails on NGM eye disease collab in wake of phase 2 fail

Over a year after Merck & Co. narrowed the scope of its long-standing collaboration with NGM Biopharmaceuticals, the Big Pharma has dropped another raft of candidates in the wake of a phase 2 fail.